Literature DB >> 16548447

The yin and yang of tumor necrosis factor inhibitors.

Leonard Calabrese1.   

Abstract

Tumor necrosis factor (TNF) inhibitors have proven highly effective against a number of autoimmune diseases but have been disappointing in treating others. An increase in the risk of Mycobacterium tuberculosis and other opportunistic infections has been noted in patients treated with these agents. If we use these drugs, we need to weigh their beneficial and adverse effects.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16548447     DOI： 10.3949/ccjm.73.3.251

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  5 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

2.  In Silico Augmentation of the Drug Development Pipeline: Examples from the study of Acute Inflammation.

Authors:  Gary An; John Bartels; Yoram Vodovotz
Journal:  Drug Dev Res       Date:  2011-03-01       Impact factor: 4.360

3.  Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.

Authors:  Irene Pontikaki; Edit Shahi; Lucretia Adina Frasin; Raffaele Gianotti; Carlo Gelmetti; Valeria Gerloni; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

4.  AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice.

Authors:  Jeremy A Goettel; Roopali Gandhi; Jessica E Kenison; Ada Yeste; Gopal Murugaiyan; Sharmila Sambanthamoorthy; Alexandra E Griffith; Bonny Patel; Dror S Shouval; Howard L Weiner; Scott B Snapper; Francisco J Quintana
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.423

Review 5.  In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.

Authors:  Chun-Ming Huang; Teruaki Nakatsuji; Yu-Tseung Liu; Yang Shi
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-01       Impact factor: 4.169
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.